Patents by Inventor Satyen Gohil

Satyen Gohil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROR1 CAR T-cells
    Patent number: 11723925
    Abstract: There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: August 15, 2023
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 ANTIBODIES
    Publication number: 20230220073
    Abstract: There is described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Application
    Filed: July 21, 2022
    Publication date: July 13, 2023
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 antibodies
    Patent number: 11466083
    Abstract: There is described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: October 11, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • BISPECIFIC ANTIBODIES TO ROR1 AND CD3
    Publication number: 20220204621
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Application
    Filed: March 18, 2022
    Publication date: June 30, 2022
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • Bispecific antibodies to ROR1 and CD3
    Patent number: 11306142
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: April 19, 2022
    Assignee: UCL Business LTD
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 CAR T-CELLS
    Publication number: 20200405759
    Abstract: There is described a chimeric antigen receptor (CAR) which comprises an antigen binding domain which selectively binds to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1), and its use. Also described is a T cell comprising the CAR and its use in the treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: December 31, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • ROR1 ANTIBODIES
    Publication number: 20200354448
    Abstract: Thereis described Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) antibodies that specifically bind a ROR1 polypeptide, and their use. In particular, isolated monoclonal antibodies are described and their use in a number of applications, including in the detection, prevention and treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 12, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta
  • BISPECIFIC ANTIBODIES TO ROR1 AND CD3
    Publication number: 20200157218
    Abstract: There is described bispecific antibodies which selectively bind to Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) and the CD3 subunit of the T-Cell Receptor (TCR), their production and their use. Also described is the use of the bispecific antibodies in the treatment of cancer.
    Type: Application
    Filed: July 5, 2018
    Publication date: May 21, 2020
    Inventors: Amit Nathwani, Satyen Gohil, Marco Della Peruta